Regeneron Stock Pops After Biotech Company Crushes Third-Quarter Views – Investor’s Business Daily

Regeneron Pharmaceuticals (REGN) crushed third-quarter estimates Tuesday and offered a bullish look at its Merck (MRK)-rivaling cancer treatment  sending Regeneron stock to a six-month high.
XOn the stock market today, Regeneron stock popped 6.9% to close at…

Click here to view the original article.